pfizer,

Latest stories

  • in Health care

    Pfizer, Biogen among hundreds of US drugmakers calling for abortion pill Mifepristone ruling reversal

    Pfizer, Biogen among hundreds of US drugmakers calling for abortion pill Mifepristone ruling reversal

    by

    US: Executives from more than 300 biotech and pharmaceutical industry companies, including Pfizer Inc and Biogen Inc, signed an open letter on Monday calling for reversal of a federal judge’s decision to suspend sales of the abortion pill mifepristone. A U.S. judge on Friday suspended the U.S. Food and Drug Administration’s 2000 approval of the drug, […] More

  • in Health care

    Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data

    Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data

    by

    New Delhi: Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine was 82 percent effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirm preliminary data from the study. Final data from the study that was halted early […] More

  • in Health care

    Pfizer, BioNTech dragged to Court over COVID vaccine patent infringement once again

    by

    US: Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc. and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus’ patents. Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines […] More

  • in Health care

    USFDA accepts Pfizer supplemental new drug applications for BRAFTOVI plus MEKTOVI

    by

    New York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. The Prescription Drug User Fee Act […] More

  • in Health care

    Pfizer gets USFDA emergency use nod for Omicron BA.4/BA.5-adapted bivalent COVID booster in children under 5 years

    by

    New York: Pfizer Inc. and BioNTech SE have announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age (also referred to as under 5 years of age) at […] More